Semaglutide (Wegovy, Ozempic) is approved for the treatment of type 2 diabetes and obesity, based on the results from the SUSTAIN and STEP phase 3 clinical trial programs, respectively
, L-,
-1, -1 2, -1 ,
The genome-scale metabolic model of humans, Recon 2.2 19 , was expanded with the viral replication reaction for each of the three viruses
Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I: Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al